| Obesity in Children |
1 |
1 |
| Obesity |
0 |
0.99 |
| Child |
0 |
0.77 |
| Bariatric Surgery |
0 |
0.61 |
| Body Mass Index |
0 |
0.59 |
| Otolaryngology |
0 |
0.54 |
| Type 2 Diabetes Mellitus |
0 |
0.42 |
| Pain Management |
0 |
0.4 |
| Adverse Effects |
0 |
0.38 |
| Head and Neck Cancer |
0 |
0.33 |
| Insurance |
0 |
0.31 |
| Patient Safety |
0 |
0.27 |
| Dentistry and Oral Health |
0 |
0.25 |
| Revenue and Practice Management |
0 |
0.22 |
| Hypertension |
0 |
0.19 |
| Biliary Disease |
0 |
0.18 |
| Health Care Reform |
0 |
0.18 |
| Cardiovascular Risk Management |
0 |
0.17 |
| Heart |
0 |
0.17 |
| Thyroid Disease |
0 |
0.17 |
| Food and Drug Administration (FDA) |
0 |
0.16 |
| Cardiac Murmur |
0 |
0.15 |
| Arrhythmia |
0 |
0.14 |
| Blood |
0 |
0.14 |
| Sleep Disorders |
0 |
0.14 |
| Surgery |
0 |
0.14 |
| Selective Serotonin-Reuptake Inhibitors |
0 |
0.13 |
| Congenital Heart Disease |
0 |
0.12 |
| Pregnancy |
0 |
0.12 |
| Anxiety |
0 |
0.1 |
| Migraine |
0 |
0.1 |
| Stigma |
0 |
0.1 |
| Glaucoma |
0 |
0.09 |
| Sleep Apnea |
0 |
0.09 |
| Abdominal Pain |
0 |
0.08 |
| Anxiety Disorder |
0 |
0.07 |
| Cardiovascular disease |
0 |
0.07 |
| Chronic Disease |
0 |
0.07 |
| Clinical Guidelines |
0 |
0.07 |
| Dizziness |
0 |
0.07 |
| Exercise |
0 |
0.07 |
| Hyperthyroidism |
0 |
0.07 |
| Kidney |
0 |
0.07 |
| Off-Label Use |
0 |
0.07 |
| Pain |
0 |
0.07 |
| Weight Loss |
0 |
0.07 |
| GLP-1 Receptor Agonist |
0 |
0.06 |
| Medullary Thyroid Cancer |
0 |
0.06 |
| Metabolic Acidosis |
0 |
0.06 |
| Monoamine Oxidase Inhibitor |
0 |
0.06 |
| Renal Failure |
0 |
0.06 |